- Home
- DMLP vs BLFS Comparison
DMLP vs BLFS Comparison
Compare DMLP & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMLP | BLFS |
|---|---|---|
| Founded | 2003 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 1989 |
Fundamental Metrics
Financial Performance| Metric | DMLP | BLFS |
|---|---|---|
| Price | $22.25 | $25.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 250.9K | ★ 360.9K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 14.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $143,803,000.00 | $100,144,000.00 |
| Revenue This Year | N/A | $20.67 |
| Revenue Next Year | N/A | $14.13 |
| P/E Ratio | $19.72 | ★ N/A |
| Revenue Growth | N/A | ★ 87.53 |
| 52 Week Low | $20.85 | $19.10 |
| 52 Week High | $34.88 | $29.62 |
Technical Indicators
Market Signals| Indicator | DMLP | BLFS |
|---|---|---|
| Relative Strength Index (RSI) | 45.48 | 48.48 |
| Support Level | $21.37 | $24.11 |
| Resistance Level | $22.43 | $25.98 |
| Average True Range (ATR) | 0.62 | 0.82 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 42.93 | 62.41 |
Price Performance
Historical ComparisonAbout DMLP Dorchester Minerals L.P.
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.